Actively Recruiting
Positron Emission Tomography (PET) Imaging of Thrombosis
Led by Massachusetts General Hospital · Updated on 2026-02-27
165
Participants Needed
1
Research Sites
565 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.
CONDITIONS
Official Title
Positron Emission Tomography (PET) Imaging of Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 85 years
- For atrial fibrillation patients: history of atrial fibrillation or paroxysmal atrial fibrillation
- For atrial fibrillation patients: Transesophageal echocardiogram (TEE) to evaluate left atrial appendage (LAA) within 14 days prior to enrollment or scheduled within 14 days
- For COVID-19 patients: positive SARS-CoV-2 RNA test by RT-PCR within the last month and not requiring mechanical ventilation
- For cancer patients: diagnosed with cancer
- For other patients: ultrasound- or CT-confirmed or high likelihood of thrombus (e.g., elevated D-dimer)
- For other patients: no thrombolytic treatment received
You will not qualify if you...
- Under 18 years of age
- Presence of electrical implants such as cardiac pacemaker or perfusion pump
- Pregnant or breastfeeding (negative pregnancy test required for females of childbearing potential)
- Claustrophobia
- Radiation exposure exceeding 50 mSv in the prior 12 months
- Unable to lie comfortably inside the PET scanner
- Direct or indirect supervision by the principal investigator
- Body weight over 300 lbs for MRI table or over 441 lbs for CT table
- Metallic or electric implants contraindicated for MR-PET scanning
- Inability to give written informed consent
- Clinically unsuitable as determined by investigators
- For atrial fibrillation patients: stroke, myocardial infarction, or major cardiac surgery within last 3 months
- For atrial fibrillation patients: chest pain or syncope within last 6 weeks unless followed by stress test or angiography
- For atrial fibrillation patients: persistent heart rate over 120 bpm or under 50 bpm
- For atrial fibrillation patients: daytime pauses greater than 3 seconds
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
D
David E Sosnovik, MD
CONTACT
A
Anne L Philip, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here